Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

por Li, Chenggong, Mei, Heng, Hu, Yu
Publicado 2020

Targeting CD22 for B-cell hematologic malignancies

por Xu, Jia, Luo, Wenjing, Li, Chenggong, Mei, Heng
Publicado 2023

Global Regulation of Differential Gene Expression by c-Abl/Arg Oncogenic Kinases

por Dong, Qincai, Li, Chenggong, Qu, Xiuhua, Cao, Cheng, Liu, Xuan
Publicado 2017

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma

por Du, Mengyi, Huang, Linlin, Kou, Haiming, Li, Chenggong, Hu, Yu, Mei, Heng
Publicado 2022

Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology

por Cao, Hongwen, Wang, Dan, Gao, Renjie, Li, Chenggong, Feng, Yigeng, Chen, Lei
Publicado 2022

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY

por Wang, Xindi, LI, Chenggong, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Xu, Jia, Mei, Heng, Hu, Yu
Publicado 2023

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy

por Wang, Xindi, Li, Chenggong, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Xu, Jia, Mei, Heng, Hu, Yu
Publicado 2023

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis

por Luo, Wenjing, Li, Chenggong, Zhang, Yinqiang, Du, Mengyi, Kou, Haiming, Lu, Cong, Mei, Heng, Hu, Yu
Publicado 2022

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

por Zhang, Yinqiang, Zhou, Fen, Wu, Zhuolin, Li, Yingnan, Li, Chenggong, Du, Mengyi, Luo, Wenjing, Kou, Haiming, Lu, Cong, Mei, Heng
Publicado 2022

Plasma proteomic and metabolomic signatures of B‐ALL patients during CAR‐T cell therapy

por Wu, Jianghua, Tang, Lu, Du, Mengyi, Li, Chenggong, Kou, Haiming, Jiang, Huiwen, Luo, Wenjing, Zhang, Yinqiang, Huang, Zhongpei, Liao, Danying, Xiong, Wei, Mei, Heng, Hu, Yu
Publicado 2023

A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance

por Si, Wengong, Shen, Jiaying, Du, Chengyong, Chen, Danni, Gu, Xidong, Li, Chenggong, Yao, Minya, Pan, Jie, Cheng, Junchi, Jiang, Donghai, Xu, Liang, Bao, Chang, Fu, Peifen, Fan, Weimin
Publicado 2018

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA

por Luo, Wenjing, LI, Chenggong, Zhang, Yinqiang, Wang, Xindi, Wu, Zhuolin, Kou, Haiming, Lu, Cong, Liao, Danying, Chen, Zejian, Chen, Caiqin, Wu, Lijun, Xiong, Wei, Deng, Jun, Hu, Yu, Mei, Heng
Publicado 2023

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report

por Li, Chenggong, Sun, Yan, Wang, Jing, Tang, Lu, Jiang, Huiwen, Guo, Tao, Liu, Lin, Wu, Yaohui, Ai, Lisha, Xia, Linghui, Wu, Jianjun, Lin, Zhicai, Qian, Qijun, Hu, Yu, Mei, Heng
Publicado 2021

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

por Zhang, Yinqiang, Li, Chenggong, Du, Mengyi, Jiang, Huiwen, Luo, Wenjing, Tang, Lu, Kang, Yun, Xu, Jia, Wu, Zhuolin, Wang, Xindi, Huang, Zhongpei, Zhang, Yanlei, Wu, Di, Chang, Alex H., Hu, Yu, Mei, Heng
Publicado 2023

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma

por Li, Chenggong, Zhou, Fen, Wang, Jing, Chang, Qi, Du, Mengyi, Luo, Wenjing, Zhang, Yinqiang, Xu, Jia, Tang, Lu, Jiang, Huiwen, Liu, Lin, Kou, Haiming, Lu, Cong, Liao, Danying, Wu, Jianghua, Wei, Qiuzhe, Ke, Sha, Deng, Jun, Liu, Cheng, Mei, Heng, Hu, Yu
Publicado 2023

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

por Mei, Heng, Li, Chenggong, Jiang, Huiwen, Zhao, Xinying, Huang, Zhiping, Jin, Dan, Guo, Tao, Kou, Haiming, Liu, Lin, Tang, Lu, Yin, Ping, Wang, Zhihui, Ai, Lisha, Ke, Sha, Xia, Yimeng, Deng, Jun, Chen, Lei, Cai, Li, Sun, Chunyan, Xia, Linghui, Hua, Gaoquan, Hu, Yu
Publicado 2021